Crown Bioscience Inc.
6.7.2017 14:02 | Nasdaq OMX
CrownBio Demonstrates Scientific Advancements in Metabolic Disease with a validated and improved translatable model for obesity and Type 2 Diabetes drug discovery
SANTA CLARA, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, announces the publication of two new scientific papers indicating that the FATZO model is a significantly improved rodent model for obesity, dysmetabolism and type 2 diabetes for pre-clinical studies.
The research conducted by CrownBio, and collaborators was published 06/22/17 in two PLOS ONE papers.
Charles Van Jackson, CSO CrownBio Indiana commented, "The FATZO mouse is an improved translatable model that provides us with a better understanding of the physiological and cellular mechanisms that lead from obesity, metabolic disorders, to diabetes. The data presented in these papers demonstrates that FATZO has several advantages over traditional rodent models and will impact the speed of drug discovery."
The FATZO model, has been developed to provide polygenic obesity and a metabolic pattern of hyperglycemia and hyperinsulinemia. These studies demonstrate that the FATZO model is a more translatable rodent model for obesity and type 2 diabetes, including for the development of anti-diabetic therapeutics.
"The publication of these papers are indicative of how CrownBio continues to further validate the translatability of this model and our commitment to bring to the market novel models that are more representative of human conditions of obesity and type 2 diabetes," said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. "These scientific advancements of translatable model development are the key to early discovery of disease and enable faster drug discovery."
For more information on CrownBio's commitment to furthering the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. firstname.lastname@example.org
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
RedHill Biopharma Ltd.25.7.2017 13:23 | pressemeddelelse
RedHill Biopharma Reports 2017 Second Quarter Financial Results
Compuware Corporation25.7.2017 12:01 | pressemeddelelse
Compuware and Wipro Jointly Launch a Mainframe Center of Excellence
VITEC25.7.2017 10:32 | pressemeddelelse
VITEC to Showcase Field-Proven Military and Defense Video Streaming Solutions at DSEI
Nasdaq25.7.2017 09:01 | pressemeddelelse
Nasdaq to Acquire Sybenetix
Novavax, Inc.24.7.2017 22:07 | pressemeddelelse
Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs
LedgerX24.7.2017 21:53 | pressemeddelelse
Announcing the First U.S. Federally Regulated Exchange and Clearing House for Digital Currency Derivatives
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum